Eur J Clin Invest . SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test

[tetano]

Eur J Clin Invest


. 2021 Apr 18;e13573.
doi: 10.1111/eci.13573. Online ahead of print.
SARS-CoV-2 antibodies: comparison of three high-throughput immunoassays versus the neutralization test


Riccardo Laterza ¹ , Annalisa Schirinzi ¹ , Rossella Bruno ² , Rosa Genco ¹ , Renato Contino ¹ , Angelo Ostuni ² , Francesca Di Serio ¹



Affiliations

• PMID: 33870493
• DOI: 10.1111/eci.13573

Abstract

On March 11, 2020 the World Health Organization (WHO) declared the novel coronavirus (SARS-CoV-2) outbreak a global pandemic.¹ Currently, no specific therapy has proved to be effective against the infection. With the approval by WHO² of the first vaccine for emergency use against SARS-CoV-2 on December 31, 2020, it is important to understand the strength and duration of immunity after administration, which is induced by neutralizing anti-SARS-CoV-2 S antibodies (nAbs).³ The same antibodies are also present in individuals once the SARS-CoV-2 infection is resolved, at levels that depend on the duration and severity of clinical symptoms.⁴ The efficacy of passive antibody therapy has been associated with the concentration of nAbs in the convalescent plasma (CP) of recovered patients.^5,6 Thus, it would be useful to immediately identify donors with high nAbs titers. The gold-standard test used to detect nAbs is the plaque reduction neutralization test (PRNT).

Keywords: Covid-19; PRNT; RBD; SARS-CoV-2; immunoassay; neutralizing antibodies.